MYGN logo

Myriad Genetics Inc. (MYGN)

$3.26

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on MYGN

Market cap

$311817843

EPS

-4.31

P/E ratio

--

Price to sales

0.39

Dividend yield

--

Beta

1.685145

Price on MYGN

Previous close

$3.18

Today's open

$3.22

Day's range

$3.18 - $3.29

52 week range

$2.74 - $8.59

Profile about MYGN

CEO

Sam Raha

Employees

2700

Headquarters

Salt Lake City, UT

Exchange

Nasdaq Global Select

Shares outstanding

95649645

Issue type

Common Stock

MYGN industries and sectors

Healthcare

Medical Diagnostics & Screening

News on MYGN

MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $MYGN--MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law.

news source

Business Wire • Aug 8, 2026

news preview

MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Myriad (MYGN) To Contact Him Directly To Discuss Their Options

news source

GlobeNewsWire • Aug 7, 2026

news preview

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Myriad Genetics (MYGN)

Myriad Genetics missed Q2 2026 revenue consensus by roughly 7%-8% -- $190.7 million against Wall Street's $206-$208 million -- and MYGN shareholders took the hit. Levi & Korsinsky is investigating potential securities law violations on behalf of MYGN investors who suffered losses. Myriad Genetics missed Q2 2026 revenue consensus by roughly 7%-8% -- $190.7 million against Wall Street's $206-$208 million -- and MYGN shareholders took the hit. Levi & Korsinsky is investigating potential securities law violations on behalf of MYGN investors who suffered losses.

news source

GlobeNewsWire • Aug 6, 2026

news preview

MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.

news source

GlobeNewsWire • Aug 6, 2026

news preview

MYGN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Myriad Genetics (MYGN)

NEW YORK--(BUSINESS WIRE)--On May 5, 2026, Myriad Genetics (NASDAQ: MYGN) reaffirmed adjusted EBITDA of $37 million to $49 million and adjusted gross margin of 68% to 69% for full-year 2026. Roughly three months later, the adjusted EBITDA range was suspended outright and MYGN shares dropped. If you held Myriad Genetics stock and lost money, you are encouraged to submit your loss information now. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (2.

news source

Business Wire • Aug 5, 2026

news preview

Myriad Genetics, Inc. (MYGN) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel

SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN) or certain of its officers and directors violated federal securities laws by misrepresenting or failing to timely disclose material information to investors.

news source

GlobeNewsWire • Aug 4, 2026

news preview

Myriad Genetics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Myriad Genetics (MYGN)

On May 5, 2026, Myriad Genetics management reaffirmed full-year revenue of $860-$880 million. Just three months later, the Company cut guidance to $770-$790 million and adjusted EBITDA guidance was suspended -- and MYGN shareholders absorbed the loss.

news source

PRNewsWire • Aug 3, 2026

news preview

Myriad Genetics, Inc. (MYGN) Q2 2026 Earnings Call Transcript

Myriad Genetics, Inc. (MYGN) Q2 2026 Earnings Call Transcript

news source

Seeking Alpha • Jul 31, 2026

news preview

Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability

Highl ights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is engaging payers and executing revenue cycle initiatives expected to improve reimbursement predictability and performance.

news source

GlobeNewsWire • Jul 30, 2026

news preview

Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates

Myriad Genetics (MYGN) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.05 per share a year ago.

news source

Zacks Investment Research • Jul 30, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Myriad Genetics Inc.

Open an M1 investment account to buy and sell Myriad Genetics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in MYGN on M1